ArriVent BioPharma Past Earnings Performance
Past criteria checks 0/6
ArriVent BioPharma's earnings have been declining at an average annual rate of -15.5%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-15.5%
Earnings growth rate
97.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -29.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How ArriVent BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -81 | 15 | 79 |
| 30 Jun 24 | 0 | -75 | 13 | 73 |
| 31 Mar 24 | 0 | -75 | 11 | 72 |
| 31 Dec 23 | 0 | -69 | 10 | 65 |
| 30 Sep 23 | 0 | -59 | 8 | 54 |
| 30 Jun 23 | 0 | -56 | 8 | 49 |
| 31 Mar 23 | 0 | -42 | 7 | 35 |
| 31 Dec 22 | 0 | -37 | 6 | 30 |
Quality Earnings: AVBP is currently unprofitable.
Growing Profit Margin: AVBP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if AVBP's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare AVBP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: AVBP has a negative Return on Equity (-29.21%), as it is currently unprofitable.